Voya Investment Management LLC purchased a new position in shares of Axovant Sciences Ltd (NYSE:AXON) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 13,941 shares of the biotechnology company’s stock, valued at approximately $323,000.
Several other large investors have also recently made changes to their positions in AXON. FMR LLC boosted its stake in shares of Axovant Sciences by 968.5% during the 2nd quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock worth $167,794,000 after acquiring an additional 6,558,462 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in shares of Axovant Sciences during the 2nd quarter worth approximately $2,141,000. Prudential Financial Inc. boosted its stake in shares of Axovant Sciences by 700.9% during the 2nd quarter. Prudential Financial Inc. now owns 80,170 shares of the biotechnology company’s stock worth $1,859,000 after acquiring an additional 70,160 shares in the last quarter. Federated Investors Inc. PA purchased a new stake in shares of Axovant Sciences during the 2nd quarter worth approximately $1,408,000. Finally, Northern Trust Corp boosted its stake in shares of Axovant Sciences by 19.4% during the 2nd quarter. Northern Trust Corp now owns 322,685 shares of the biotechnology company’s stock worth $7,482,000 after acquiring an additional 52,334 shares in the last quarter.
Several equities research analysts have recently commented on AXON shares. Jefferies Group LLC set a $40.00 price target on Axovant Sciences and gave the stock a “buy” rating in a research note on Friday, August 25th. BidaskClub lowered Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Evercore ISI started coverage on Axovant Sciences in a research note on Friday, September 8th. They set an “outperform” rating and a $30.00 price target on the stock. Chardan Capital reissued a “sell” rating and set a $3.00 price target on shares of Axovant Sciences in a research note on Saturday, September 23rd. Finally, Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price target on the stock in a research note on Monday, October 9th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $14.13.
WARNING: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/14/voya-investment-management-llc-purchases-shares-of-13941-axovant-sciences-ltd-axon.html.
Shares of Axovant Sciences Ltd (AXON) opened at $5.11 on Tuesday. Axovant Sciences Ltd has a 52 week low of $4.60 and a 52 week high of $27.98. The company has a quick ratio of 6.01, a current ratio of 6.01 and a debt-to-equity ratio of 0.25.
Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12).
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd (NYSE:AXON).
Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.